WuXi STA launches parenteral formulation manufacturing line at Wuxi
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
This product is based on Osmotic Controlled Release Oral Delivery System technology
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
The joint venture will help both the parties to further develop the high-margin service business
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India
The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness
Subscribe To Our Newsletter & Stay Updated